Literature DB >> 9332551

Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified?

M Murphy, A E Brown, K A Sepkowitz, E M Bernard, T E Kiehn, D Armstrong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9332551     DOI： 10.1086/516925

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  4 in total

1.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.

Authors:  W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

2.  Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.

Authors:  M Oethinger; A S Jellen-Ritter; S Conrad; R Marre; W V Kern
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

3.  A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation.

Authors:  Noemí Puig; Javier de la Rubia; Isidro Jarque; Miguel Salavert; Pau Montesinos; Jaime Sanz; Guillermo Martín; Guillermo Sanz; Susana Cantero; Ignacio Lorenzo; Miguel A Sanz
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

4.  Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit.

Authors:  T Saito; S Yoshioka; Y Iinuma; S Takakura; N Fujihara; T Ichinohe; T Ishikawa; T Uchiyama; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03       Impact factor: 3.267
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.